IL Therapeutics

From Wikipedia, the free encyclopedia
Jump to: navigation, search
IL Therapeutics Inc.
Industry Biotechnology
Headquarters 105E ñ 111 Research Drive, Saskatoon, SK, Canada

IL Therapeutics Inc. was previously owned by Western Life Sciences Venture Fund LP (“Western Life Sciences”) and in 2006 its shares were purchased by Pacgen Biopharmaceuticals Corporation (“Pacgen”).[1]

History[edit]

Saskatchewan Research Council operates a bio-processing laboratory which facilitated biomedical research. IL Therapeutics was developed from research first begun at the Western College of Veterinary Medicine

Pharmaceuticals[edit]

Currently IL Therapeutics is working on a drug candidate, IL-8(3-73)K11R/G31P (“PAC-G31P”) for relief of Acute Respiratory Distress Syndrome (ARDS)[2] The Saskatchewan Research council, SRC also assisted with the funding of this project through the Agriculture Development Fund - SRC Industry Venture Fund.[3] The successful progression of G31PRecently the University of Saskatchewan Industry Liaison Office (ILO) decided to commercialize a commercialize this new drug treatment.[4] This research has been sponsored by a $3 million boost from the Western Life Sciences Venture Fund (WLS)[4]

See also[edit]

References[edit]

  1. ^ Pacgen Biopharmaceuticals Corporation, Pacgen Biopharmaceuticals Acquires IL Therapeutics Inc. (PDF), retrieved Sep 9, 2007 
  2. ^ Pacgen Biopharmaceuticals Corporation, Pacgen Biopharmaceuticals Acquires IL Therapeutics Inc., retrieved Sep 9, 2007 
  3. ^ Saskatchewan Research Council 2005-2006 Annual Report, Sustainable Science Solutions, retrieved Sep 9, 2007 
  4. ^ a b U of S News Releases: University Communication, U of S News Releases: U of S Signs Letter of Intent to Commercialize Treatment for Lung Injury Complications, retrieved Sep 9, 2007 

External links[edit]